Edit
Akari Therapeutics
https://www.akaritx.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 30.03.2023
Active
We develop life-transforming treatments for autoinflammatory & orphan diseases involving the complement (C5) and leukotriene (LTB4) pathways.
Investors 2
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Vivo Capit... | vivocapita... |
Mentions in press and media 8
| Date | Title | Description |
| 30.03.2023 | Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering | - |
| 12.09.2022 | Akari Therapeutics Announces $12.75 Million Registered Direct Offering | NEW YORK and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced it has entered into d... |
| 04.01.2022 | Akari Therapeutics : Announces $6.0 Million Registered Direct Offering - Form 6-K | Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering NEW YORK and LONDON, December 30, 2021 - Akari Therapeutics, Plc (Nasdaq: AKTX) ("Akari" or the "Company"), a biopharmaceutical company focused on... |
| 30.12.2021 | Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering | NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases wh... |
| 30.12.2021 | Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering | NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases wh... |
| 22.09.2021 | Akari Therapeutics : International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium 2021 Poster | ARREST-BP: A Randomised Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Nomacopan therapy in Bullous Pemphigoid patients Pascal Joly1, Victoria Werth2, Christian D. Sadik3, Miles Nunn4, Sanjeev Khindri4, Russell Hall... |
| 29.12.2016 | Why the complement system is set to shine | Humans also have an innate immune system that, among other things, activates antibodies and tags dubious cells for destruction. It does this through a biological cascade known as the complement system. After a slow start, the race is on to ... |
| - | Why the complement system is set to shine | When drug development and the immune system collide we get CAR-T, checkpoint inhibitors, oncolytic vaccines, monoclonal antibodies and more. These fields have produced many therapies and garnered a lot of media attention in recent years. Bu... |